BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21566092)

  • 1. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
    Treon SP; Soumerai JD; Hunter ZR; Patterson CJ; Ioakimidis L; Kahl B; Boxer M
    Blood; 2011 Jul; 118(2):276-81. PubMed ID: 21566092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
    Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
    Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
    Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
    Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab.
    Zeitlinger MA; Schmidinger M; Zielinski CC; Chott A; Raderer M
    Leuk Lymphoma; 2005 May; 46(5):771-4. PubMed ID: 16019517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment.
    Owen RG; Hillmen P; Rawstron AC
    Clin Lymphoma; 2005 Mar; 5(4):278-81. PubMed ID: 15794865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
    Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
    Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Osterborg A
    Blood; 2002 Aug; 100(3):768-73. PubMed ID: 12130484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T
    BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
    Chakraverty R; Orti G; Roughton M; Shen J; Fielding A; Kottaridis P; Milligan D; Collin M; Crawley C; Johnson P; Clark A; Parker A; Bloor A; Pettengell R; Snowden J; Pettitt A; Clark R; Hale G; Peggs K; Thomson K; Morris E; Mackinnon S
    Blood; 2010 Oct; 116(16):3080-8. PubMed ID: 20587785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
    Albitar M; Do KA; Johnson MM; Giles FJ; Jilani I; O'Brien S; Cortes J; Thomas D; Rassenti LZ; Kipps TJ; Kantarjian HM; Keating M
    Cancer; 2004 Sep; 101(5):999-1008. PubMed ID: 15329909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab in B-cell chronic lymphocytic leukemia.
    Shapira I; Grossbard ML
    Clin Lymphoma; 2004 Mar; 4(4):228-9. PubMed ID: 15072614
    [No Abstract]   [Full Text] [Related]  

  • 13. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
    Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
    Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
    Zhu WM; Li Y; Yu C; Li N; Li JS
    Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
    Dunleavy K; Wilson WH
    Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
    [No Abstract]   [Full Text] [Related]  

  • 16. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
    O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
    Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
    Faderl S; Thomas DA; O'Brien S; Garcia-Manero G; Kantarjian HM; Giles FJ; Koller C; Ferrajoli A; Verstovsek S; Pro B; Andreeff M; Beran M; Cortes J; Wierda W; Tran N; Keating MJ
    Blood; 2003 May; 101(9):3413-5. PubMed ID: 12522009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
    Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
    Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
    Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
    Ishizawa K; Fukuhara N; Nakaseko C; Chiba S; Ogura M; Okamoto A; Sunaga Y; Tobinai K
    Jpn J Clin Oncol; 2017 Jan; 47(1):54-60. PubMed ID: 28122892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.